Measuring Oncological Value of Exercise and Statin (MOVES)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515109-24-00

Acronym

MOVES

Enrollment

240

Registered

2024-08-20

Start date

2023-03-31

Completion date

Unknown

Last updated

2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic breast, ovarian, prostate and kidney cancer

Brief summary

Cancer progression (based on radiological, biochemical or clinical evaluation) and mortality (evaluated by time from starting 1. line cancer treatment to death)

Interventions

DRUGLipistad 40 mg kalvopäällysteiset tabletit

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Cancer progression (based on radiological, biochemical or clinical evaluation) and mortality (evaluated by time from starting 1. line cancer treatment to death)	—

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026